# VentiRx Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ventirx-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Seattle, US
- Website: www.ventirx.com
- Total disclosed funding: $103M
- Latest round: Series B (Sep 23, 2014)
- Investors on record: 6

## About

Founded in 2006 and based in Washington, US, VentiRx Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing medicines for the treatment of cancer, respiratory, and autoimmune diseases.

## Funding rounds

- Series B, Sep 23, 2014, $51M — ARCH Venture Partners, Domain Associates, Frazier Healthcare Partners, MedImmune Ventures, Bristol-Myers Squibb Company
- Series B, Mar 1, 2012, $4.6M — ARCH Venture Partners, Domain Associates, Frazier Healthcare Partners, AstraZeneca
- Series B, Jan 8, 2010, $13M — ARCH Venture Partners, Domain Associates, Frazier Healthcare Partners, MedImmune Ventures
- Series A, May 29, 2008, $9M — ARCH Venture Partners, Domain Associates
- Series B, Mar 6, 2007, $26M — ARCH Venture Partners, Domain Associates, Frazier Healthcare Partners

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series B, Series A
- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series B, Series A
- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series B
- MedImmune Ventures (https://capitalatlas.ai/funds/medimmune-ventures) — Series B
- AstraZeneca — Series B
- Bristol-Myers Squibb Company — Series B